I believe the price target for Bioventus can easily be $45. It is a new IPO for a company w/ 700+ employees, disruptive orthobiologics and surgical methods, and high growth potential. Support just needs to pickup. That said, please do your own due diligence and invest at your own risk. Everything I say is on an opinion based basis.